Autopsy report · NCT01806064
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Cause of deathFutility
“The study did not meet endpoint.”
Life of this trial
- Ran for about 6 years 3 months before it stopped.
- 173 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Tracon Pharmaceuticals Inc.
- Sponsor type
- Industry
- Conditions
- Renal Cell Carcinoma
- Interventions
- TRC105 and Axitinib; Axitinib
- Participants
- 173
- Sites
- 39
- Countries
- Czechia, Hungary, United Kingdom, United States
Trials that died the same way
- A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
“The primary endpoint was not achieved in the study.” - Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
“The study was terminated as its Part A did not meet the primary endpoint.” - Gastric and Autonomic Functions in Patients With Intragastric Balloon
“The study did not recruit any participant.” - Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
“Company decided to terminate this study due to study did not meet the primary endpoint.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.